The Federal Court has dismissed two infringement actions brought against defendants under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations), following a common trial on the validity of Canadian Patent No. 2,562,277 (277 Patent
Pharmaceutical cases
Federal Court dismisses motion for determination of an issue of law under the new PM(NOC) Regulations

By Pharma in Brief team on
The Federal Court dismissed Pharmascience Inc.’s (Pharmascience) motion to determine a question of law on the issue of whether a first person can commence an action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (…
Top Headlines of 2018

By Kristin Wall on
Last year ushered in a number of changes to the Canadian pharmaceutical and life sciences sector. 2018 also served as a year to explore the impacts of major intellectual property decisions and regulatory changes from 2017 including the impact of…
Current directions in regulatory and intellectual property law in Canadian pharmaceutical cases

By Pharma in Brief team on
Recent pharmaceutical cases in regulatory and intellectual property law have resulted in developments on several fronts, including:
- regulatory matters;
- patent validity and damages;
- Patented Medicines (Notice of Compliance) Regulations proceedings; and
- class actions.
In this paper, we review some of…